Regenerative medicine company that uses induced pluripotent stem (iPS) cells, has raised $22 million.

JULY 10, 2010 By Robert Graham -- Regenerative medicine
company that uses induced pluripotent stem (iPS) cells, has
raised $22 million.

Hybrid Medical Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing.

Bacteria communicate with one another using chemical signal
molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing,detecting, and responding to small hormone-like molecules termed autoinducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-
controlled processes are unproductive when undertaken by
an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is ccomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication.


Regenerative medicine company that uses induced pluripotent
stem (iPS) cells, has raised $22 million in Series B funding. Google Ventures led the round, and was joined by Mitsubishi UFJ Capital, ATEL Ventures and return backers MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases,” said Dr. Yeshwant. ”The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will ramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission.”

Hybrid Medical Analytics has been and will be a Leader in this space.